Table 1 Clinical characteristics
From: Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy
Effective group (n = 14) | Non-effective group (n = 21) | P value | |
|---|---|---|---|
Age (years) | 59.4 ± 19.4 | 61.2 ± 13.2 | 0.76 |
Gender (M/F) | 6/8 | 9/12 | 1.00 |
IOP before administration of ripasudil (mmHg) | 22.8 ± 3.7 | 21.4 ± 4.4 | 0.33 |
IOP after administration of ripasudil (mmHg) | 19.0 ± 3.5 | 23.4 ± 8.0 | 0.10 |
Refractive error (D) | −4.6 ± 4.7 | − 4.7 ± 4.9 | 0.92 |
Axial length (mm) | 24.6 ± 1.7 | 25.5 ± 3.2 | 0.44 |
Central corneal thickness (m) | 522.7 ± 31.9 | 530.1 ± 48.6 | 0.61 |
Preoperative IOP (mmHg) | 27.4 ± 6.2 | 24.8 ± 3.9 | 0.14 |
Lens status | 1.00 | ||
Phakia | 12 | 18 | |
Pseudophakia | 2 | 3 | |
HFA30–2 MD (dB) | −7.4 ± 4.1 | −12.2 ± 6.4 | 0.03 |
Glaucoma medications | 3.2 ± 2.0 | 3.4 ± 1.5 | 0.73 |
PGA + β blocker + CAI | 3 | 6 | |
PGA + β blocker + CAI + brimonidine | 2 | 7 | |
PGA + CAI + brimonidine | 0 | 0 | |
PGA + CAI | 0 | 1 | |
β blocker + CAI + brimonidine | 0 | 0 | |
Others | 9 | 7 | |